Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAM-201 in Relapsed/Refractory T-ALL or T-LL
NCT05885464Phase 2Active, not recruiting
- Sponsor
- Beam Therapeutics
- Start
- May 2023
- Primary completion
- Dec 2026
- Modality
- Gene Editing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of BEAM-201 in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL) (2 arms), sponsored by Beam Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 25 months and Overall Response Rate at 25 months. Started May 2023; status: active, not recruiting.
02
Drugs
BEAM-201
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT05885464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885464.